These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 30220228)

  • 21. Rectal 5-aminosalicylic acid for induction of remission in ulcerative colitis.
    Marshall JK; Thabane M; Steinhart AH; Newman JR; Anand A; Irvine EJ
    Cochrane Database Syst Rev; 2010 Jan; (1):CD004115. PubMed ID: 20091560
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Budesonide for the treatment of ulcerative colitis.
    Abdalla MI; Herfarth H
    Expert Opin Pharmacother; 2016 Aug; 17(11):1549-59. PubMed ID: 27157244
    [TBL] [Abstract][Full Text] [Related]  

  • 23. How important is onset of action in ulcerative colitis therapy?
    Masson S; Nylander D; Mansfield JC
    Drugs; 2005; 65(15):2069-83. PubMed ID: 16225364
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A review of infliximab use in ulcerative colitis.
    Wilhelm SM; McKenney KA; Rivait KN; Kale-Pradhan PB
    Clin Ther; 2008 Feb; 30(2):223-30. PubMed ID: 18343261
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Unfractionated or low-molecular weight heparin for induction of remission in ulcerative colitis.
    Chande N; McDonald JW; Macdonald JK
    Cochrane Database Syst Rev; 2008 Apr; (2):CD006774. PubMed ID: 18425969
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Immunosuppressants for therapy of patients with ulcerative colitis].
    Hisamatsu T; Hibi T
    Nihon Rinsho; 2005 May; 63(5):831-5. PubMed ID: 15881178
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment of ulcerative colitis.
    Blonski W; Buchner AM; Lichtenstein GR
    Curr Opin Gastroenterol; 2014 Jan; 30(1):84-96. PubMed ID: 24285003
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ulcerative proctitis: an update on the pharmacotherapy and management.
    Gecse KB; Lakatos PL
    Expert Opin Pharmacother; 2014 Aug; 15(11):1565-73. PubMed ID: 24837209
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A practical guide to the management of distal ulcerative colitis.
    Ardizzone S; Bianchi Porro G
    Drugs; 1998 Apr; 55(4):519-42. PubMed ID: 9561342
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Contemporary Management of Ulcerative Colitis.
    Vanga R; Long MD
    Curr Gastroenterol Rep; 2018 Mar; 20(3):12. PubMed ID: 29589185
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Appropriateness and long-term discontinuation rate of biological therapies in ulcerative colitis.
    Maillard MH; Bortolotti M; Vader JP; Mottet C; Schoepfer A; Gonvers JJ; Burnand B; Froehlich F; Michetti P; Pittet V;
    J Crohns Colitis; 2014 Aug; 8(8):825-34. PubMed ID: 24462322
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Novel extended release budesonide formulation for treatment of ulcerative colitis.
    Farkas K; Molnár T
    Expert Opin Pharmacother; 2014 Jan; 15(1):131-7. PubMed ID: 24219763
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Anti-TNF-alpha therapy in ulcerative colitis].
    Lakatos PL; Lakatos L
    Orv Hetil; 2008 May; 149(20):921-7. PubMed ID: 18467261
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Review article: evolving concepts in treatment and disease modification in ulcerative colitis.
    Hanauer SB
    Aliment Pharmacol Ther; 2008 Mar; 27 Suppl 1():15-21. PubMed ID: 18307645
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Maintenance treatment with azathioprine in ulcerative colitis: outcome and predictive factors after drug withdrawal.
    Cassinotti A; Actis GC; Duca P; Massari A; Colombo E; Gai E; Annese V; D'Albasio G; Manes G; Travis S; Porro GB; Ardizzone S
    Am J Gastroenterol; 2009 Nov; 104(11):2760-7. PubMed ID: 19623172
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prevalence and Risk Factors for Therapy Escalation in Ulcerative Colitis in the Swiss IBD Cohort Study.
    Safroneeva E; Vavricka SR; Fournier N; Straumann A; Rogler G; Schoepfer AM
    Inflamm Bowel Dis; 2015 Jun; 21(6):1348-58. PubMed ID: 25806845
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Golimumab for moderately to severely active ulcerative colitis.
    Kedia S; Ahuja V; Makharia GK
    Expert Rev Clin Pharmacol; 2016 Oct; 9(10):1273-82. PubMed ID: 27498886
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety evaluation of ustekinumab for moderate-to-severe ulcerative colitis.
    Miyoshi J; Matsuura M; Hisamatsu T
    Expert Opin Drug Saf; 2022 Jan; 21(1):1-8. PubMed ID: 34511011
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Review article: integrating budesonide-MMX into treatment algorithms for mild-to-moderate ulcerative colitis.
    Danese S; Siegel CA; Peyrin-Biroulet L
    Aliment Pharmacol Ther; 2014 May; 39(10):1095-103. PubMed ID: 24641622
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mucoadhesive chitosan hydrogels as rectal drug delivery vessels to treat ulcerative colitis.
    Xu J; Tam M; Samaei S; Lerouge S; Barralet J; Stevenson MM; Cerruti M
    Acta Biomater; 2017 Jan; 48():247-257. PubMed ID: 27769943
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.